A critical review of ustekinumab for the treatment of active ulcerative colitis in adults

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017 [cited 2022 Oct 23];389(10080):1756–1770. doi: 10.1016/S0140-6736(16)32126-2
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Prim. 2020 [[cited 2023 Jan 12]];6. Available from: https://pubmed.ncbi.nlm.nih.gov/32913180/
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570–1583.
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel JF, Sands BE, et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis [Internet]. Clin Gastroenterol Hepatol 2016 [cited 2022 Dec 27];14:1245–55.e8. doi: 10.1016/j.cgh.2016.01.015.
   PubMed Web of Science ®Google Scholar
• Christensen B, Hanauer SB, Erlich J, et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol 2017 [[cited 2023 Jan 12]];15:1557–1564.e1. doi: 10.1016/j.cgh.2017.02.016.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011 [[cited 2023 Jan 12]];141:1194–1201. doi: 10.1053/j.gastro.2011.06.054.
   PubMed Web of Science ®Google Scholar
• Gupta A, Yu A, Peyrin-Biroulet L, et al. Treat to target: the role of histologic healing in inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:1800–13.e4.
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002 [[cited 2022 May 19]];347:417–429. doi: 10.1056/NEJMra020831.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006 [[cited 2022 Apr 17]];12:4807–4812. doi: 10.3748/wjg.v12.i30.4807.
   PubMed Web of Science ®Google Scholar
• Allocca M, Furfaro F, Fiorino G, et al. Can IL-23 be a good target for ulcerative colitis? Best Pract Res Clin Gastroenterol 2018 [[cited 2023 Jan 15]];32–33:95–102. doi: 10.1016/j.bpg.2018.05.016.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003 [[cited 2023 Jan 15]];278:1910–1914. doi: 10.1074/jbc.M207577200.
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation [Internet]. J Clin Invest. 2006 [cited 2023 Jan 15];116:1218–1222. doi: 10.1172/JCI28508.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting [Internet]. Nat Rev Gastroenterol Hepatol. 2019 [cited 2023 Jan 15];16:185–196. doi: 10.1038/s41575-018-0084-8.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 [[cited 2023 Jan 11]];353:2462–2476. doi: 10.1056/NEJMoa050516.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012 [[cited 2023 Jan 11]];142:257–265.e3. doi: 10.1053/j.gastro.2011.10.032.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014 [[cited 2023 Jan 11]];146:85–95. doi: 10.1053/j.gastro.2013.05.048.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013 [[cited 2022 Jul 2]];369:699–710. doi: 10.1056/NEJMoa1215734.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, D’haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2021 [[cited 2022 Jul 10]];385:1280–1291. doi: 10.1056/NEJMoa2033617.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017 [[cited 2022 Jul 2]];376:1723–1736. doi: 10.1056/NEJMoa1606910.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Danese S, Loftus EV, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 2021 [[cited 2022 Jul 11]];397:2372–2384. doi: 10.1016/S0140-6736(21)00666-8.
   PubMed Web of Science ®Google Scholar
• Parigi TL, Iacucci M, Ghosh S. Blockade of IL-23: what is in the Pipeline? J Crohn’s Colitis. 2022 [[cited 2022 Dec 21]];16:II64–72. doi: 10.1093/ecco-jcc/jjab185.
   Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 [[cited 2022 Dec 29]];371:1665–1674. doi: 10.1016/S0140-6736(08)60725-4.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 [[cited 2022 Dec 29]];371:1675–1684. doi: 10.1016/S0140-6736(08)60726-6.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013 [[cited 2022 Dec 29]];382:780–789. doi: 10.1016/S0140-6736(13)60594-2.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, m. Ann Rheum Dis 2014 [[cited 2022 Dec 29]];73:990–999. doi: 10.1136/annrheumdis-2013-204655.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for crohn’s disease. N Engl J Med 2016 [[cited 2022 Jul 2]];375:1946–1960. doi: 10.1056/NEJMoa1602773.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. InternetAvailable from 2019 [[cited 2022 Dec 21]];381:1201–1214. doi: 10.1056/NEJMoa1900750.
   PubMed Web of Science ®Google Scholar
• Boal Carvalho P, Cotter J. Mucosal healing in ulcerative colitis: a comprehensive review [Internet]. Drugs. 2017 [cited 2022 Dec 29];77:159–173. doi: 10.1007/s40265-016-0676-y.
   PubMed Web of Science ®Google Scholar
• Abreu MT, Rowbotham DS, Danese S, et al. Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension. J Crohns Colitis. 2022 [[cited 2023 Jan 10]];16:1222–1234. 10.1093/ecco-jcc/jjac030.
   PubMed Web of Science ®Google Scholar
• Danese S, Sands BE, Abreu MT, et al. Early symptomatic improvement after ustekinumab therapy in patients with ulcerative colitis: 16-week data from the UNIFI trial. Clin Gastroenterol Hepatol 2022 [[cited 2023 Jan 11]];20:2858–2867.e5. doi: 10.1016/j.cgh.2022.02.050.
   PubMed Web of Science ®Google Scholar
• Li K, Marano C, Zhang H, et al. Relationship between combined histologic and endoscopic endpoints and efficacy of ustekinumab treatment in patients with ulcerative colitis. Gastroenterology 2020 [[cited 2022 Dec 21]];159:2052–2064. doi: 10.1053/j.gastro.2020.08.037.
   PubMed Web of Science ®Google Scholar
• Hibi T, Imai Y, Murata Y, et al. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn’s disease: a subpopulation analysis of phase 3 induction and maintenance studies. Intest Res 2017 [[cited 2023 Mar 7]];15:475–486. doi: 10.5217/ir.2017.15.4.475.
   PubMedGoogle Scholar
• Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014 [[cited 2023 Mar 7]];46:1017–1020. doi: 10.1038/ng.3060.
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Kim HJ, Motoya S, et al. Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI). Intest Res 2021 [[cited 2022 Dec 31]];19:386–397. doi: 10.5217/ir.2020.00080.
   PubMed Web of Science ®Google Scholar
• Bamias G, Rivera-Nieves J, Mantzaris GJ. Efficacy of IL12/23 blockade expands our therapeutic targets and challenges the old dogma in ulcerative colitis [internet]. Gastroenterology. 2020 [cited 2023 Jan 11];158:1836–1837. doi: 10.1053/j.gastro.2020.03.024.
   PubMedGoogle Scholar
• Biancone L, Ardizzone S, Armuzzi A, et al. Ustekinumab for treating ulcerative colitis: an expert opinion [Internet]. Expert Opin Biol Ther. 2020 [[cited 2022 Dec 29]. Available from];20:1321–1329. doi: 10.1080/14712598.2020.1792882.
   PubMed Web of Science ®Google Scholar
• Hindryckx P, Novak G, Vande Casteele N, et al. Review article: dose optimisation of infliximab for acute severe ulcerative colitis [Internet]. Aliment Pharmacol Ther 2017 [cited 2023 Jan 11];45:617–630. doi: 10.1111/apt.13913.
   PubMed Web of Science ®Google Scholar
• Vieujean S, Caron B, Jairath V, et al. Is it time to include older adults in inflammatory bowel disease trials? A call for action. Lancet Heal Longev 2022 [cited 2022 Dec 29];3:e356–366. doi: 10.1016/S2666-7568(22)00060-5.
   PubMedGoogle Scholar
• Ha C, Ullman TA, Siegel CA, et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012 [[cited 2022 Dec 29]];10:1002–1007. doi: 10.1016/j.cgh.2012.02.004.
   PubMed Web of Science ®Google Scholar
• Pugliese D, Armuzzi A. Difference in treatment outcomes between clinical trials and “real-life” clinical practice: ustekinumab in ulcerative colitis [Internet]. Gastroenterol J United Eur. 2020 [cited 2022 Dec 29];8:11–12. doi: 10.1177/2050640619900575.
   PubMed Web of Science ®Google Scholar
• Ochsenkühn T, Tillack C, Szokodi D, et al. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. United Eur Gastroenterol J 2020 [[cited 2022 Dec 21]];8:91–98. doi: 10.1177/2050640619895361.
   PubMed Web of Science ®Google Scholar
• Amiot A, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther 2020 [[cited 2022 Dec 21]];51:1039–1046. doi: 10.1111/apt.15717.
   PubMed Web of Science ®Google Scholar
• Fumery M, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther 2021 [[cited 2022 Dec 21]];54:944–951. doi: 10.1111/apt.16544.
   PubMed Web of Science ®Google Scholar
• Dalal RS, Mitri J, Goodrick H, et al. Real-world comparison of tofacitinib vs ustekinumab among bio-exposed patients with ulcerative colitis: a propensity score analysis. Inflamm Bowel Dis 2021 [[cited 2022 Dec 21]];27:1694–1697. doi: 10.1093/ibd/izab097.
   PubMed Web of Science ®Google Scholar
• Chiappetta MF, Viola A, Mastronardi M, et al. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther 2021 [[cited 2022 Dec 21]];21:1483–1489. doi: 10.1080/14712598.2021.1981855.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Garre A, Iborra M, et al. Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohn’s Colitis 2021 [[cited 2022 Dec 21]];15:1846–1851. doi: 10.1093/ecco-jcc/jjab070.
   Google Scholar
• Dalal RS, Esckilsen S, Barnes EL, et al. Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study [internet]. Clin Gastroenterol Hepatol. 2021 [[cited 2022 Dec 5]. Available from];20:2399–2401.e4. doi: 10.1016/j.cgh.2021.03.028.
   PubMed Web of Science ®Google Scholar
• Honap S, Al-Hillawi L, Baillie S, et al. Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study. Frontline Gastroenterol 2022 [[cited 2023 Jan 13]];13:517–523. doi: 10.1136/flgastro-2022-102168.
   PubMed Web of Science ®Google Scholar
• Thunberg J, Björkqvist O, Hedin CRH, et al. Ustekinumab treatment in ulcerative colitis: real-world data from the Swedish inflammatory bowel disease quality register. United Eur Gastroenterol J. InternetAvailable from 2022 [[cited 2022 Dec 20]];10:631–639. doi: 10.1002/ueg2.12275.
   PubMed Web of Science ®Google Scholar
• Alsoud D, De Hertogh G, Compernolle G, et al. Real-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis. J Crohn’s Colitis. InternetAvailable from 2022 [[cited 2023 Jan 12]];16:1562–1570. doi: 10.1093/ecco-jcc/jjac067.
   Google Scholar
• Fumery M, Peyrin-Biroulet L, Nancey S, et al. Effectiveness and safety of ustekinumab intensification at 90 mg every 4 weeks in crohn’s disease: a multicentre study. J Crohn’s Colitis 2021 [[cited 2022 Dec 17]];15:222–227. doi: 10.1093/ecco-jcc/jjaa177.
   Google Scholar
• de Jong MJ, Huibregtse R, Masclee AAM, et al. Patient-reported outcome measures for use in clinical trials and clinical practice in inflammatory bowel diseases: a systematic review [Internet]. Clin Gastroenterol Hepatol. 2018 [cited 2023 Jan 12];16:648–663.e3. doi: 10.1016/j.cgh.2017.10.019
   PubMed Web of Science ®Google Scholar
• Hjortswang H, Järnerot G, Curman B, et al. The short health scale: a valid measure of subjective health in ulcerative colitis. Scand J Gastroenterol 2006 [[cited 2023 Jan 13]];41:1196–1203. doi: 10.1080/00365520600610618.
   PubMed Web of Science ®Google Scholar
• Honap S, Meade S, Ibraheim H, et al. Effectiveness and safety of ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis. Dig Dis Sci. InternetAvailable from. 2022 [[cited 2022 Dec 31]];67:1018–1035. DOI:10.1007/s10620-021-06932-4
   PubMed Web of Science ®Google Scholar
• Thunberg J, Björkqvist O, Hedin CRH, et al. Ustekinumab treatment in ulcerative colitis: real-world data from the Swedish inflammatory bowel disease quality register. United Eur Gastroenterol J 2022 [[cited 2023 Jan 14]];10:631–639. 10.1002/ueg2.12275.
   PubMed Web of Science ®Google Scholar
• Chateau T, Peyrin-Biroulet L. Two cases of inflammatory bowel disease patients treated with ustekinumab 90 mg every 3 weeks [Internet]. Inflamm Bowel Dis. 2020 [cited 2023 Jan 15];26:e7. doi: 10.1093/ibd/izz291.
   PubMed Web of Science ®Google Scholar
• Dalal RS, Pruce JC, Allegretti JR. Long-Term outcomes after ustekinumab dose intensification for inflammatory bowel diseases. Inflamm Bowel Dis. Internet 2022 [[cited 2023 Jan 13]. doi: 10.1093/ibd/izac164
   Web of Science ®Google Scholar
• Yzet C, Diouf M, Singh S, et al. No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis [Internet]. Clin Gastroenterol Hepatol 2021 [cited 2022 Dec 26];19:668–679.e8. doi: 10.1016/j.cgh.2020.06.071.
   PubMed Web of Science ®Google Scholar
• Peter CD, Huang Y, Tian W. Dual biologic therapy for severe ulcerative colitis, concomitant extraintestinal manifestations and an orbital osteoma: a successful treatment. Rev Española Enfermedades Dig. 2022;114. [[cited 2023 Jan 13]]. doi: 10.17235/reed.2022.8964/2022
   PubMed Web of Science ®Google Scholar
• Papp KA, Langholff W. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) errata. J Drugs Dermatol. 2020;19:571–572. [[cited 2022 Dec 29]]. Available from https://jddonline.com/articles/safety-surveillance-for-ustekinumab-and-other-psoriasis-treatments-from-the-psoriasis-longitudinal-a-S1545961615P0706X/
   PubMedGoogle Scholar
• Engel T, Yung DE, Ma C, et al. Effectiveness and safety of Ustekinumab for Crohn’s disease; systematic review and pooled analysis of real-world evidence. Dig Liver Dis 2019 [[cited 2022 Dec 29]];51:1232–1240. doi: 10.1016/j.dld.2019.05.002.
   PubMedGoogle Scholar
• López-Ferrer A, Laiz A, Puig L. The safety of ustekinumab for the treatment of psoriatic arthritis. Expert Opin Drug Saf. 2017 [[cited 2022 Dec 29]];16:733–742. doi: 10.1080/14740338.2017.1323864.
   PubMed Web of Science ®Google Scholar
• Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. J Am Acad Dermatol 2017 [[cited 2022 Dec 30]];77:845–854.e5. doi: 10.1016/j.jaad.2017.07.013.
   PubMed Web of Science ®Google Scholar
• Khanna R, Afif W, Ustekinumab for Ulcerative Colitis [Internet]. Gastroenterology; 2021 [cited 2023 Jan 14]. p. 2184–2186. Available from: https://pubmed.ncbi.nlm.nih.gov/33548233/.
   Google Scholar
• Cheng D, Kochar BD, Cai T, et al. Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor α antagonists in inflammatory bowel diseases. Clin Gastroenterol Hepatol 2022 [cited 2022Dec 29];20:2366–2372.e6. doi: 10.1016/j.cgh.2022.01.013.
   PubMed Web of Science ®Google Scholar
• Hasan B, Tandon KS, Miret R, et al. Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy. J Gastroenterol Hepatol 2022 [[cited 2022 Dec 26]];37:1016–1021. doi: 10.1111/jgh.15806.
   PubMed Web of Science ®Google Scholar
• Axelrad J, Colombel JF, Scherl E, et al. P729 the SAPPHIRE registry: safety of immunosuppression in a prospective cohort of inflammatory bowel disease patients with a HIstoRy of CancEr. J Crohn’s Colitis 2020 [[cited 2022 Dec 29]];14:S585–587. doi: 10.1093/ecco-jcc/jjz203.857.
   Google Scholar
• Honap S, Irving PM, Samaan MA. Ustekinumab-induced inflammatory demyelinating polyneuropathy in a patient with ulcerative colitis. J Crohn’s Colitis. 2022 [[cited 2022 Dec 26]; Available from];17:144–145. doi:10.1093/ecco-jcc/jjac116.
   Google Scholar
• Badat Y, Meissner WG, Laharie D. Demyelination in a patient receiving ustekinumab for refractory Crohn’s disease [Internet]. J Crohn’s Colitis. 2014 [cited 2022 Dec 30];8:1138–1139. Available from: https://pubmed.ncbi.nlm.nih.gov/24572561/
   Google Scholar
• Osman G, Shah K, Khan MS, et al. Ustekinumab related CIDP in a patient with psoriatic arthritis. Neurology. 2018 [[cited 2022 Dec 30]];90. InternetAvailable from: https://scholarlycommons.henryford.com/neurology_mtgabstracts/32
   Web of Science ®Google Scholar
• Jordan A, Kinnucan J. Ustekinumab-associated posterior reversible encephalopathy syndrome in a patient with crohn’s disease. ACG Case Reports J. 2022 [[cited 2023 Mar 5]];9:e00867. Available from: https://pubmed.ncbi.nlm.nih.gov/36212237/.
   PubMed Web of Science ®Google Scholar
• Mishra A, Seril DN. Posterior reversible encephalopathy syndrome following ustekinumab induction for crohn’s disease [Internet]. Case Rep Gastroenterol. 2018 [cited 2023 Mar 5];12:521–527. Available from: https://pubmed.ncbi.nlm.nih.gov/30283287/
   PubMedGoogle Scholar
• Didona D, Cunha T, Hinterseher J, et al. Dyshidrosiform pemphigoid induced by ustekinumab in a patient with ulcerative colitis [Internet]. J Eur Acad Dermatol Venereol. 2022 [[cited 2022 Dec 30]. Available from];37. doi: 10.1111/jdv.18686
   PubMed Web of Science ®Google Scholar
• Marin M, Alzueta N, Castresana M, et al. Bullous pemphigoid induced by ustekinumab: a case report. Eur J Hosp Pharm 2021 [[cited 2022 Dec 30]];28:47–49. doi: 10.1136/ejhpharm-2018-001849.
   PubMedGoogle Scholar
• Gutiérrez A, Rodríguez-Lago I. How to optimize treatment with ustekinumab in inflammatory bowel disease: lessons learned from clinical trials and real-world data [Internet]. Front Med (Lausanne). 2021 [[cited 2023 Jan 14];8. DOI: 10.3389/fmed.2021.640813
   Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Marano C, et al. Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol 2020 [[cited 2023 Jan 12]];18:2244–55.e9. doi: 10.1016/j.cgh.2019.11.059.
   PubMed Web of Science ®Google Scholar
• Shao J, Xu Z, Xu Y. Integrated population pharmacokinetic analysis of ustekinumab across multiple immune-mediated inflammatory disease populations and healthy subjects. Eur J Drug Metab Pharmacokinet. 2022 [[cited 2023 Jan 12]];47:537–548. Available from: https://pubmed.ncbi.nlm.nih.gov/35442011/
   PubMed Web of Science ®Google Scholar
• Restellini S, Afif W. Update on tdm (Therapeutic drug monitoring) with ustekinumab, vedolizumab and tofacitinib in inflammatory bowel disease [Internet]. J Clin Med. 2021;1–16. Available from: https://pubmed.ncbi.nlm.nih.gov/33802816/. cited 2023 Jan 12.
   PubMed Web of Science ®Google Scholar
• Shmais M, Regueiro M, Hashash JG. Proactive versus reactive therapeutic drug monitoring: why, when, and how? Inflamm Intest Dis. 2022 [cited 2023 Jan 12];7:50–58. doi: 10.1159/000518755.
   PubMedGoogle Scholar
• Scheffe N, Schreiner R, Thomann A, et al. Development of a mass spectrometry-based method for quantification of ustekinumab in serum specimens. Ther Drug Monit 2020 [[cited 2023 Mar 5]];42:572–577. doi: 10.1097/FTD.0000000000000734.
   PubMed Web of Science ®Google Scholar
• Burgevin A, Caron B, Sasson A, et al. Comparative safety of ustekinumab and vedolizumab in older patients with inflammatory bowel disease: a bicentric cohort study. J Clin Med 2022 [[cited 2023 Jan 15]];11:6967. doi: 10.3390/jcm11236967.
   PubMed Web of Science ®Google Scholar
• Gebeyehu GG, Fiske J, Liu E, et al. Ustekinumab and vedolizumab are equally safe and effective in elderly crohn’s disease patients. Dig Dis Sci. 2022. [cited 2023 Jan 15. Available from: https://pubmed.ncbi.nlm.nih.gov/36436155/
   PubMed Web of Science ®Google Scholar
• Fiske J, Liu E, Limdi JK, et al. Safety and effectiveness of ustekinumab in elderly Crohn’s disease patients. Eur J Gastroenterol Hepatol 2022 [[cited 2023 Jan 15]];34:1132–1139. doi: 10.1097/MEG.0000000000002436.
   PubMed Web of Science ®Google Scholar
• Garg R, Aggarwal M, Butler R, et al. Real-world effectiveness and safety of ustekinumab in elderly crohn’s disease patients. Dig Dis Sci 2022 [[cited 2023 Jan 15]];67:3138–3147. doi: 10.1007/s10620-021-07117-9.
   PubMed Web of Science ®Google Scholar
• Hahn GD, Golovics PA, Wetwittayakhlang P, et al. Safety of biological therapies in elderly inflammatory bowel diseases: a systematic review and meta-analysis [Internet]. J Clin Med. 2022 [[cited 2023 Jan 15];11:4422. doi: 10.3390/jcm11154422.
   PubMed Web of Science ®Google Scholar
• Klenske E, Osaba L, Nagore D, et al. Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with crohn’s disease. J Crohn’s Colitis 2019 [[cited 2022 Dec 31]];13:267–269. doi: 10.1093/ecco-jcc/jjy153.
   Google Scholar
• Rowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation. J Crohn’s Colitis 2018 [[cited 2022 Dec 31]];12:376–378. doi: 10.1093/ecco-jcc/jjx141.
   Google Scholar
• Chaparro M, Donday MG, Abad-Santos F, et al. The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. Therap Adv Gastroenterol 2021 [[cited 2022 Dec 31]];14:175628482110180. doi: 10.1177/17562848211018097.
   Web of Science ®Google Scholar
• Greenup AJ, Rosenfeld G, Bressler B. Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience. Scand J Gastroenterol. 2017 [[cited 2022 Dec 16]];52:1354–1359. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/28885058/
   PubMed Web of Science ®Google Scholar
• Venturin C, Nancey S, Danion P, et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol. 2017 [[cited 2022 Dec 31]];17. Available from: https://pubmed.ncbi.nlm.nih.gov/28629323/
   PubMed Web of Science ®Google Scholar
• Cortes X, Borrás-Blasco J, Antequera B, et al. Ustekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther 2017 [[cited 2022 Dec 31]];42:234–236. doi: 10.1111/jcpt.12492.
   PubMed Web of Science ®Google Scholar
• Galli-Novak E, Mook SC, Büning J, et al. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis [Internet]. J Eur Acad Dermatol Venereol 2016 [cited 2022 Dec 31];30:e191–192. doi: 10.1111/jdv.13499.
   PubMed Web of Science ®Google Scholar
• Wils P, Seksik P, Stefanescu C, et al. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Aliment Pharmacol Ther. 2021 [[cited 2022 Dec 31]];53:460–470. Available from https://pubmed.ncbi.nlm.nih.gov/33345331/
   PubMed Web of Science ®Google Scholar
• Biemans VBC, Van Der Meulen-De Jong AE, Van Der Woude CJ, et al. Ustekinumab for crohn’s disease: results of the icc registry, a nationwide prospective observational cohort study. J Crohn’s Colitis 2020 [[cited 2022 Dec 31]];14:33–45. doi: 10.1093/ecco-jcc/jjz119.
   Google Scholar
• Verstockt B, Dreesen E, Noman M, et al. Ustekinumab exposure-outcome analysis in crohn’s disease only in part explains limited endoscopic remission rates. J Crohn’s Colitis 2019 [[cited 2022 Dec 12]];13:864–872. doi: 10.1093/ecco-jcc/jjz008.
   Google Scholar
• Gisbert JP, Chaparro M. Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: a review [internet]. Drugs. 2020 [cited 2022 Dec 31];80:1085–1100. Available from: https://pubmed.ncbi.nlm.nih.gov/32562207/
   PubMed Web of Science ®Google Scholar
• Ashat D, Jain A, Weaver KN, et al. An old bridge to the newer biologics: cyclosporine for rescue therapy in acute severe ulcerative colitis. Dig Dis Sci 2022 [[cited 2022 Dec 30]];67:5439–5443. doi: 10.1007/s10620-022-07682-7.
   PubMed Web of Science ®Google Scholar
• Guillo L, D’amico F, Danese S, et al. Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review [internet]. J Crohn’s Colitis 2021 [cited 2023 Jan 11];15:1236–1243. doi: 10.1093/ecco-jcc/jjaa260.
   Google Scholar
• Chateau T, Angioi K, Peyrin-Biroulet L. Two cases of successful ustekinumab treatment for non-infectious uveitis associated with crohn’s disease [Internet]. J Crohn’s Colitis. 2020 [cited 2023 Jan 15];14:571. Available from: https://pubmed.ncbi.nlm.nih.gov/31606743/.
   Google Scholar
• Hollywood A, Murray G, Fleming S, et al. Ustekinumab in the management of hidradenitis suppurativa: a retrospective study. J Drugs Dermatol. 2022 [[cited 2023 Jan 15]];21:319–320. InternetAvailable from https://pubmed.ncbi.nlm.nih.gov/35254749/
   PubMedGoogle Scholar
• Montero-Vilchez T, Pozo-Román T, Sánchez-Velicia L, et al. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J DermatolTreat 2022 [[cited 2023 Jan 15]];33:348–353. doi: 10.1080/09546634.2020.1755008.
   Google Scholar
• Romaní J, Vilarrasa E, Martorell A, et al. Ustekinumab with intravenous infusion: results in hidradenitis suppurativa. Dermatology 2020 [[cited 2023 Jan 15]];236:21–24. doi: 10.1159/000501075.
   PubMed Web of Science ®Google Scholar
• Hu KA, Shen J, Rieger K, et al. Subcutaneous sweet syndrome successfully treated with ustekinumab in a patient with ulcerative colitis. ACG Case Reports J 2022 [[cited 2022 Dec 30]];9:e00881. doi: 10.14309/crj.0000000000000881.
   PubMed Web of Science ®Google Scholar
• Paul N, Lazarev M, Montemayor K, et al. Cavitary lung nodules as an extraintestinal manifestation of ulcerative colitis. BMJ Case Rep 2022 [[cited 2022 Dec 26]];15:e251976. doi: 10.1136/bcr-2022-251976.
   PubMedGoogle Scholar
• Wu J, Smogorzewski J. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases [Internet]. Dermatol Ther. 2021 [[cited 2022 Dec 30];34. DOI: 10.1111/dth.14883
   Web of Science ®Google Scholar
• Fries W, Demarzo MG, Navarra G, et al. Ulcerative colitis in adulthood and in older patients: same disease, same outcome, same risks? Drugs Aging 2022 [cited 2022 Dec 31];39:441–452. doi: 10.1007/s40266-022-00943-0.
   PubMed Web of Science ®Google Scholar
• Puchner A, Gröchenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation: a consensus report issued by the Austrian societies of gastroenterology and hepatology and rheumatology and rehabilitation. Wien Klin Wochenschr 2019 [[cited 2023 Jan 12]];131:29–44. doi: 10.1007/s00508-019-1448-y.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the american gastroenterological association IBD parenthood project working group. Gastroenterology 2019 [[cited 2022 Jun 27]];156:1508–1524. doi: 10.1053/j.gastro.2018.12.022.
   PubMed Web of Science ®Google Scholar
• AlAmeel T, Al Sulais E. Ustekinumab and pregnancy: continue or cease before you conceive? Gastroenterology. 2019 [cited 2023 Jan 12];157:1435. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/31513799/.
   PubMed Web of Science ®Google Scholar
• Shaffer SR, Traboulsi C, Krugliak Cleveland N, et al. Combining cyclosporine with ustekinumab in acute severe ulcerative colitis. ACG Case Reports J 2021 [[cited 2022 Dec 30]];8:e00604. doi: 10.14309/crj.0000000000000604.
   PubMed Web of Science ®Google Scholar
• Ganzleben I, Geppert C, Osaba L, et al. Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis. Therap Adv Gastroenterol 2020 [[cited 2022 Dec 30]];13:175628482095411. doi: 10.1177/1756284820954112.
   Web of Science ®Google Scholar
• Veyrard P, Pellet G, Laharie D, et al. Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis [Internet]. Clin Gastroenterol Hepatol. 2022 [[cited 2023 Jan 11]. doi: 10.1016/j.cgh.2022.03.008
   Web of Science ®Google Scholar
• Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999 [[cited 2022 Dec 30]];94:1587–1592. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/10364029/.
   PubMed Web of Science ®Google Scholar
• Segal JP, Quraishi MN. Lack of evidence for the use of ustekinumab for acute severe ulcerative colitis [Internet]. United Eur. Gastroenterol J. 2021 [cited 2022 Dec 26];9:127. Available from: https://onlinelibrary.wiley.com/doi/full/10.1177/2050640620972959.
   Google Scholar
• Herfarth HH, Long MD, Isaacs KL Use of biologics in pouchitis a systematic review [Internet]. J. Clin. Gastroenterol; 2015 [cited 2022 Dec 30]. p. 647–654. Available from: https://pubmed.ncbi.nlm.nih.gov/26084005/.
   Google Scholar
• Tran-Minh ML, Allez M, Gornet JM. Successful treatment with ustekinumab for chronic refractory pouchitis [Internet]. J Crohn’s Colitis. 2017 [cited 2022 Dec 30];11:1156. Available from: https://academic.oup.com/ecco-jcc/article/11/9/1156/2983512.
   Google Scholar
• Ollech JE, Rubin DT, Glick L, et al. Ustekinumab is effective for the treatment of chronic antibiotic-refractory pouchitis. Dig Dis Sci 2019 [[cited 2022 Dec 30]];64:3596–3601. doi: 10.1007/s10620-019-05697-1.
   PubMed Web of Science ®Google Scholar
• Dalal RS, Gupta S, Goodrick H, et al. Outcomes of standard and intensified dosing of ustekinumab for chronic pouch disorders. Inflamm Bowel Dis 2022 [[cited 2023 Jan 11]];28:146–149. doi: 10.1093/ibd/izab156.
   PubMed Web of Science ®Google Scholar
• Singh S, Murad MH, Fumery M, et al. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis [Internet]. Clin Gastroenterol Hepatol 2020 [cited 2023 Jan 14];18:2179–2191.e6. doi: 10.1016/j.cgh.2020.01.008.
   PubMed Web of Science ®Google Scholar
• Meyer A, Fumery M, Peyrin-Biroulet L, et al. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. Scand J Gastroenterol 2022 [[cited 2023 Jan 13]];57:1454–1462. doi: 10.1080/00365521.2022.2095668.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Peyrin-Biroulet L. Positioning therapies in ulcerative colitis [Internet]. Clin Gastroenterol Hepatol. 2020 [cited 2023 Jan 14];18:1280–90.e1. Available from: https://pubmed.ncbi.nlm.nih.gov/31982609/
   PubMed Web of Science ®Google Scholar